Filter by content type
Filter by year
Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 14, 2020 - … Earnings Approaching key topline data in non-small cell lung cancer and Huntington’s disease Advancing plans to … Accomplishments: Presented updated interim data from the CLASSICAL-Lung Phase 1b/2 study of the company’s lead product … . Pepinemab Clinical Updates: Non-Small Cell Lung Cancer - CLASSICAL-Lung Clinical Trial . The company’s ongoing …
Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 14, 2020 - … will be released by early October 2020 . Non-Small Cell Lung Cancer (NSCLC). CLASSICAL-Lung clinical trial . The CLASSICAL-Lung study is evaluating pepinemab in combination …
Vaccinex Announces up to $16.5 Million in Equity Financing Agreements and Provides an Update on COVID-19 Impact on its Clinical Programs
March 31, 2020 - … Key trials in Huntington’s disease and non-small cell lung cancer are near completion; company working with trial … and will provide further updates as warranted. CLASSICAL-Lung. The CLASSICAL-Lung study is evaluating pepinemab in combination …
Vaccinex Presents Updated Interim Results from a Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting
June 3, 2019 - … Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting … Vaccinex … of the presentation, presented “Interim results from CLASSICAL-Lung, a phase 1b/2 study of pepinemab (VX15/2503) … the many subject volunteers and clinicians involved in the CLASSICAL-Lung clinical trial with whom we share a hope for …
Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 17, 2021 - … head and neck cancer Announced publication of results from CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell lung cancer … Announced the publication of results from the CLASSICAL-Lung phase 1b/2 clinical trial in non-small cell …
Vaccinex Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
March 13, 2019 - … (VX15/2503) in combination with avelumab in non-small cell lung cancer expected in 2Q 2019 Enrollment in cohort B of the … Cell Lung Cancer (NSCLC). The dose escalation phase of the CLASSICAL–Lung clinical trial, in which the Company is … release of initial open label data from our ongoing CLASSICAL - Lung trial in non-small cell lung cancer during …
Vaccinex Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 13, 2018 - … trials in cancer and Huntington’s Disease Enrollment in CLASSICAL Lung Cancer trial and Cohort B of the SIGNAL Huntington’s … Non-Small Cell Lung Cancer (NSCLC). In the company’s CLASSICAL study, which is evaluating pepinemab in combination …
Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth International Cancer lmmunotherapy Conference in Paris, France
September 27, 2019 - … in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer in Podium and Poster Presentations at the Fifth … for Cancer Research (AACR). Updated Interim Data The CLASSICAL-Lung trial is being conducted in collaboration with … our plans, expectations and objectives with respect to the CLASSICAL-Lung clinical trial, the combination of pepinemab …
Vaccinex Announces Three Oral Presentations Highlighting Semaphorin 4D (SEMA4D) at the ASCO-SITC Clinical Immuno-Oncology Symposium
February 6, 2020 - … in a Phase 1b/2 study in patients with non-small cell lung cancer (NSCLC). Interim results that we recently … the event. Visit the website at www.vaccinex.com . About CLASSICAL – Lung Vaccinex is currently evaluating its novel … , Darmstadt, Germany . The clinical trial, short-named “CLASSICAL – Lung”, is a multi-center, open-label study …
Vaccinex Presents Updated Interim Data from a Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 9, 2019 - … in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the 34th Annual Meeting of the Society for … from the poster presentation. Updated Interim Data The CLASSICAL-Lung trial is being conducted in collaboration with … of the Company’s website, www.vaccinex.com . About the CLASSICAL – Lung Clinical Trial The design of the trial …
Pagination
- Previous page
- Page 2
- Next page